A controlled study of fluvoxamine and exposure in obsessive-compulsive disorder.
DSM-3 obsessive-compulsive out-patients were randomly assigned to fluvoxamine with antiexposure (F), fluvoxamine with exposure (Fe), or placebo with exposure (Pe) for 24 weeks. Of 65 patients offered treatment 60 entered the trial, 50 reached week 8, 44 completed treatment to week 24, and 37 reached follow up to week 48. On average the patient had depressed mood (mean Hamilton depression rating scale = 19). Drop-out numbers, clinical status and behavioural measures were comparable across groups. Most F patients did not do antiexposure, but Fe and Pe patients complied in doing exposure. All three groups improved in rituals and depression from week 0 to week 24 and 48, with a slight but non-significant superiority for combined treatment up to week 24. At week 8 there was a drug between-group effect on rituals, but not on depression. At week 24 there was a drug between-group effect on depression, but not on rituals. The drug superiority was short-lived. At week 48 there was no between-group difference in rituals or depression. Depression was related to ritual outcome at week 24 in F, and tended to be so in Fe.
Cottraux
J
J
Laboratoire de Psychologie Médicale, Hôpital Neurologique, Lyon, France.
Mollard
E
E
Bouvard
M
M
Marks
I
I
Sluys
M
M
Nury
A M
AM
Douge
R
R
Cialdella
P
P
D000328:Adult; D000928:Antidepressive Agents / Q000627:therapeutic use*; D003863:Depression / Q000503:physiopathology; D005260:Female; D016666:Fluvoxamine; D006801:Humans; D008297:Male; D008875:Middle Aged; D009771:Obsessive-Compulsive Disorder / Q000188:drug therapy* / Q000503:physiopathology; D010091:Oximes / Q000627:therapeutic use*; D010349:Patient Compliance; D011569:Psychiatric Status Rating Scales; D016032:Randomized Controlled Trials as Topic
D000928:Antidepressive Agents; D010091:Oximes; D016666:Fluvoxamine